Literature DB >> 27208714

Chronic Pain and the Opioid Conundrum.

Lynn R Webster1.   

Abstract

Opioids prescribed for chronic cancer and noncancer pain have been embroiled in public policy debates as to effectiveness and potential for contributing to society's problem with misuse, addiction, and overdose mortality. The conundrum of opioid prescribing is to determine who will most likely benefit from opioids and how medical practitioners may safely provide chronic opioid therapy, while also identifying patients who are unlikely to benefit or could divert illicit pharmaceuticals into society. Risk assessment and monitoring are essential to meet the standard of care, as is compliance with federal controlled substances law as well as state regulations.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic pain; Government; Opioid analgesics; Policy; Practice guidelines

Mesh:

Substances:

Year:  2016        PMID: 27208714     DOI: 10.1016/j.anclin.2016.01.002

Source DB:  PubMed          Journal:  Anesthesiol Clin        ISSN: 1932-2275


  4 in total

1.  Sustained Benefits of Exercise-based Motivational Interviewing, but Only among Nonusers of Opioids in Patients with Fibromyalgia.

Authors:  Sunghye Kim; James E Slaven; Dennis C Ang
Journal:  J Rheumatol       Date:  2016-12-01       Impact factor: 4.666

Review 2.  Hydrocodone Bitartrate ER (Hysingla® ER): A Review in Chronic Pain.

Authors:  Sohita Dhillon
Journal:  Clin Drug Investig       Date:  2016-11       Impact factor: 2.859

3.  Examining patterns in opioid prescribing for non-cancer-related pain in Wales: preliminary data from a retrospective cross-sectional study using large datasets.

Authors:  Emma Davies; Ceri Phillips; Jaynie Rance; Berni Sewell
Journal:  Br J Pain       Date:  2018-09-25

4.  Taking adolescent prescription opioid use in context: risk stratification in early mid-life based on medical and nonmedical use.

Authors:  Jennifer Hah
Journal:  Pain       Date:  2016-10       Impact factor: 7.926

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.